The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
Abstract
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There are genetically determined differences in the activity of this enzyme. The genotypes of CYP2C19 are classified into the three groups, rapid extensive metabolizer (RM), intermediate metabolizer (IM), and poor metabolizer (PM). The pharmacokinetics and pharmacodynamics of PPIs depend on CYP2C19 genotype status. Plasma PPI levels and intragastric pHs during PPI treatment in the RM group are lowest, those in the IM group come next, and those in the PM group are highest of the three groups. These CYP2C19 genotype-dependent differences in pharmacokinetics and pharmacodynamics of PPIs influence the cure rates for the gastro-esophageal reflux disease and H. pylori infection by PPI-based therapies. For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Kuipers, E. J., Lundell, L., Klinkenberg-Knol, E. C., Havu, N., Festen, H. P. M., Liedman, B., Lamers, C. B. H. W., Jansen, J. B. M. J., Dalenbäck, J., Snel, P., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341603 · Cited by 769
De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09788-3 · Cited by 752
Lind, T., van Zanten, S. V., Unge, P., Spiller, R., Bayerdörffer, E., O'Morain, C., Bardhan, K. D., Bradette, M., Chiba, N., Wrangstadh, M., et al. (1996) · Helicobacter · doi:10.1111/j.1523-5378.1996.tb00027.x · Cited by 573
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
Lind, T., Mégraud, F., Unge, P., Bayerdörffer, E., O'Morain, C., Spiller, R., van Zanten, S. V., Bardhan, K. D., Hellblom, M., Wrangstadh, M., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70119-8 · Cited by 434
Ishizaki, & Horai (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00022.x · Cited by 428
The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease
Walsh, J. H., & Peterson, W. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331508 · Cited by 383
Gastric precancerous process in a high risk population: cohort follow-up.
Correa, P., Haenszel, W. M., Cuello, C., Zavala, D., Fontham, E., Zarama, G., Tannenbaum, S. R., Collazos, T., & Ruiz, B. (1990) · PubMed · Cited by 375
The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPase
Sachs, G., Shin, J. M., Briving, C., Wallmark, B., & Hersey, S. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001425 · Cited by 367
Cited by
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shi, S., & Klotz, U. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0538-y · Cited by 314
Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH
Kirchheiner, J., Glatt, S., Fuhr, U., Klotz, U., Meineke, I., Seufferlein, T., & Brockmöller, J. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0576-5 · Cited by 277
Acid Suppression Therapy: Where Do We Go from Here?
Scarpignato, C., Pelosini, I., & Di Mario, F. (2006) · Digestive Diseases · doi:10.1159/000091298 · Cited by 119
Pachkoria, K., Lucena, M. I., Ruiz‐Cabello, F., Crespo, E., Cabello, M. R., Andrade, R. J., & on behalf of the Spanish Group for the Study of Drug‐Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM) (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707122 · Cited by 49
Tulain, U. R., Ahmad, M., & Rashid, A. (2018) · Polymer-Plastics Technology and Engineering · doi:10.1080/03602559.2018.1434668 · Cited by 16
Metadata
- Authors
- Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A., & Ishizaki, T.
- Venue
- Drug Metabolism and Pharmacokinetics
- Published
- 2005
- Volume
- 20
- Issue
- 3
- Pages
- 153-167
- ISSN
- 1347-4367 (ISSN-L)
- OpenAlex
- W2056770708
- Cited by
- 257
- References
- 76
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies. https://app.cochat.ai/papers/10.2133/dmpk.20.153
- The paper
- Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A., & Ishizaki, T. (2005). Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies. Drug Metabolism and Pharmacokinetics. https://doi.org/10.2133/dmpk.20.153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.